Thus, research including other in vivo and patient-relevant in vitro models is needed to further unravel the downstream consequences of TUBA4A downregulation, and how this contributes to ALS-related neurodegeneration. This evidence concerns the gene TUBA4A and amyotrophic lateral sclerosis.